Landscape Capital Management L.L.C. Sells 180,717 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Landscape Capital Management L.L.C. trimmed its holdings in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 29.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 424,725 shares of the company’s stock after selling 180,717 shares during the period. Landscape Capital Management L.L.C.’s holdings in Trevi Therapeutics were worth $1,419,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in TRVI. Vanguard Group Inc. increased its holdings in Trevi Therapeutics by 2.7% during the first quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock worth $7,948,000 after buying an additional 60,249 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new position in Trevi Therapeutics in the first quarter valued at about $47,000. Opaleye Management Inc. grew its position in shares of Trevi Therapeutics by 4.3% during the 1st quarter. Opaleye Management Inc. now owns 2,645,000 shares of the company’s stock valued at $9,125,000 after acquiring an additional 110,000 shares during the period. Rosalind Advisors Inc. increased its stake in shares of Trevi Therapeutics by 50.3% during the 2nd quarter. Rosalind Advisors Inc. now owns 1,391,577 shares of the company’s stock worth $4,147,000 after purchasing an additional 465,561 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of Trevi Therapeutics by 38.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 178,511 shares of the company’s stock worth $532,000 after purchasing an additional 49,884 shares during the period. 95.76% of the stock is currently owned by institutional investors.

Trevi Therapeutics Trading Down 1.4 %

Shares of TRVI opened at $2.73 on Friday. The firm has a fifty day moving average price of $3.12 and a 200-day moving average price of $2.91. The firm has a market capitalization of $209.86 million, a P/E ratio of -6.20 and a beta of 1.01. Trevi Therapeutics, Inc. has a 12-month low of $0.97 and a 12-month high of $4.00.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same period last year, the company earned ($0.08) earnings per share. Analysts predict that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Insider Buying and Selling at Trevi Therapeutics

In other news, CEO Jennifer L. Good sold 10,981 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total transaction of $33,162.62. Following the sale, the chief executive officer now directly owns 213,313 shares of the company’s stock, valued at $644,205.26. The trade was a 4.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 21,595 shares of company stock worth $64,886 over the last three months. Corporate insiders own 24.37% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on TRVI. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Trevi Therapeutics in a report on Tuesday, October 22nd. Needham & Company LLC reiterated a “buy” rating and set a $8.00 price objective on shares of Trevi Therapeutics in a research report on Friday, November 8th. EF Hutton Acquisition Co. I upgraded Trevi Therapeutics to a “strong-buy” rating in a report on Monday, August 19th. Leerink Partners assumed coverage on shares of Trevi Therapeutics in a report on Monday, September 9th. They issued an “outperform” rating and a $7.00 price target on the stock. Finally, Raymond James initiated coverage on shares of Trevi Therapeutics in a report on Friday, August 30th. They issued an “outperform” rating and a $9.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $7.43.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.